Navigation Links
Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
Date:12/3/2010

EAST HANOVER, N.J., Dec. 3, 2010 /PRNewswire/ -- A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa® (zoledronic acid) significantly improved overall survival (OS) and progression-free survival (PFS) in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs) (1,2).

The published results are from Medical Research Council (MRC) Myeloma IX, a large, randomized, Phase III clinical trial of nearly 2,000 patients with multiple myeloma (1). These results were initially reported at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, in June 2010.

At a median follow-up of 3.7 years, Zometa significantly reduced the risk for death by 16% (hazard ratio [HR] 0.842; 95% confidence interval [CI] 0.74-0.96; P=0.0118) and the relative risk for PFS events by 12% (HR 0.88; 0.80-0.98; P=0.0179) compared with oral clodronate. In addition to demonstrating superiority to clodronate on survival endpoints, Zometa was significantly superior to clodronate in the prevention of SREs associated with multiple myeloma, regardless of SRE history at baseline (1).

More than 750,000 cases of multiple myeloma are diagnosed each year worldwide, with a median overall survival of three to five years (3). Nearly 95% of advanced stage multiple myeloma patients have bone disease and half of them will experience SREs (e.g., pathologic fractures, radiation or surgery to bone, spinal cord compression) if not treated (4,5).

"As a hematologist who treats patients with multiple myeloma, the survival benefit demonstrated by Zometa in this study is very encouraging," said Professor Gareth Morgan, Head of Haemato-oncology at The Royal Marsden and The Institute of Cancer Research, UK and one of the study's lead in
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
2. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
3. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
4. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
5. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
6. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
7. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
8. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
9. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
10. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
11. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Wash. and VANCOUVER , ... OGXI ) announced today that it will report its ... 2015. Company management will host a conference call and ... an overview of financial results, clinical development programs and ... the webcast, log on to the Investor Relations page ...
(Date:7/30/2015)... July 30, 2015 PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the second quarter ending June ... many fronts across the organization.  We are excited to ... dystrophy clinical trial ever conducted with topline results expected ... Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is now ...
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized traditional ... (API), provided updates regarding the notice it received on ... "Exchange") indicating that the Company was below certain of ... Sections 134 and 1101 of the NYSE MKT Company ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
(Date:8/1/2015)... ... August 01, 2015 , ... Western University ... trending profession” that comprises a growing percentage of U.S. physicians, and reflects the ... was one part of the message delivered by John W. Becher, DO, president ...
(Date:8/1/2015)... ... 01, 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural ... by the National Retail Federation, the largest retail trade association in the world, for ... business owners to be named as such. According to the NRF’s website, Retail Champions ...
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, and ... download on the Apple AppStore. , The app is designed to track various ... as a tool to view personal health and use this information for positive behavior ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... What are the STASH awards? The Significant Technological Achievements in Secretive Horticulture ... community as well as tried-and-true products that have stood the test of time. ...
(Date:7/31/2015)... ... August 01, 2015 , ... Super Bowl 50 will emanate from Levi’s ... biggest day each year is the Super Bowl. In the two weeks that separate the ... the host venue. The 2016 Super Bowl game will mark the 50th time it has ...
Breaking Medicine News(10 mins):Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5Health News:Local Retail Advocate Wins National Recognition 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2
... a type of cholesterol-lowering drug, found that although the ... did inhibit expression of cellular markers of immune activation ... activation and inflammation are associated with progression of HIV ... disease progression and help in the infection,s management. The ...
... 16 (HealthDay News) -- The way women draw themselves ... researchers suggest. They found that women with anorexia ... without eating disorders. The study, by Israeli researchers, ... women with no eating disorder, half of them overweight ...
... , WEDNESDAY, Feb. 16 (HealthDay News) -- ... are least likely to be physically active in their ... States where residents are the least likely to ... Louisiana, Mississippi, Oklahoma and Tennessee. Physical inactivity rates are ...
... Minnesota research team was recently awarded two grants ... Science Foundation,s Cyber-Enabled Discovery and MRI Programs to ... will assist with the early diagnosis of children ... attention deficit disorder (ADD) and obsessive compulsive disorder ...
... who consider dropping out are particularly sensitive to a handful ... according to a study led by Michigan State University scholars. ... the family and students, failure to get their intended major ... drop out, said Tim Pleskac, MSU assistant professor of psychology ...
... Latino siblings of children developmental disabilities such as ... including anxiety and lower school performance, according to a ... Children,s Research Center. "When a child has ... including siblings," said lead author Debra Lobato, Ph.D., of ...
Cached Medicine News:Health News:Trial suggests statin may affect markers associated with progression of HIV 2Health News:Self-Drawings May Reveal Hidden Eating Disorders 2Health News:Appalachia, the South Home to Least-Active Americans: CDC 2Health News:University of Minnesota researchers study the use of computer vision to diagnose mental disorders 2Health News:MSU-led study identifies risks for quitting college 2Health News:Latino siblings of children with developmental disabilities at risk 2Health News:Latino siblings of children with developmental disabilities at risk 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: